Agios Pharmaceuticals (AGIO) Operating Expenses (2012 - 2026)

Agios Pharmaceuticals' Operating Expenses history runs 15 years deep, the most recent figure standing at $130.8 million for Q1 2026.

• Quarterly Operating Expenses rose 13.36% year-over-year to $130.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $541.6 million (up 13.46% YoY) and the FY2025 annual result came in at $526.2 million, up 13.83% from the prior year.
• Operating Expenses was $130.8 million for Q1 2026 at Agios Pharmaceuticals, down from $141.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $141.5 million in Q4 2025 and bottomed at $94.6 million in Q3 2022.
• A 5-year average of $114.2 million and a median of $111.8 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses decreased 5.64% — and 2025, when it increased 21.92%.
• Agios Pharmaceuticals' Operating Expenses stood at $103.5 million in 2022, then advanced by 9.56% to $113.4 million in 2023, then grew by 19.75% to $135.8 million in 2024, then grew by 4.26% to $141.5 million in 2025, then slipped by 7.61% to $130.8 million in 2026.
• Business Quant data shows AGIO's Operating Expenses at $130.8 million in Q1 2026, $141.5 million in Q4 2025, and $129.7 million in Q3 2025.